INTRODUCTION AND FINANCIAL SUMMARY The Smith & Nephew Group the Group is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy which includes arthroscopic procedures referred to as sports medicine and advanced wound management, with revenue of approximately $4 billion in 2010.
Smith & Nephew plc the Company is the parent company of the Group.
It is an English public limited company with its shares listed on the premium list of the UK Listing Authority and traded on the London Stock Exchange.
Shares are also traded on the New York Stock Exchange in the formof AmericanDepositary Shares ADSs.
This is the Annual Report of Smith & Nephew plc for the year ended 31 December 2010.
It comprises, in a single document, the Annual Report and Accounts of the company in accordance with UK requirements and the Annual Report on Form 20-F in accordance with the regulations of the United States Securities and Exchange Commission SEC.
Smith & Nephews corporate website, www.
com, gives additional information on the Group, including an electronic version of this Annual Report.
Information made available on this website, or other websites mentioned in this Annual Report, are not, and should not be regarded as being, part of orincorporated into this Annual Report.
For the convenience of the reader, a Glossary of technical and financial terms used in this document is included on page 152.
The product names referred to in this document are identified by use of capital letters and are trademarks owned by or licensed to members of the Group.
Financial Summary 2010 2009 2008 Financial Highlights i iii $ million $ million $ million Revenue 3,962 3,772 3,801 Underlying growth in revenue % 4% 2% 6% Trading profit 969 857 776 Underlying growth in trading profit % 11% 15% 6% Trading profit margin % 24.5% 22.7% 20.4% Operating profit 920 723 630 Attributable profitforthe year 615 472 377 Adjusted attributable profit 654 580 493 Basic earnings per OrdinaryShare 69.3 53.4 42.6 EPSA 73.6 65.6 55.6 Growth in EPSA % 12% 18% 7% Dividends per OrdinaryShare ii 15.82 14.39 13.08 Cash generated fromoperations 1,111 1,030 815 Trading cash flow 825 771 612 Trading profit to cash conversion % 85% 90% 79% i Items .
ii The Board has proposed a final dividend of 9.82 US cents per share which together with the firstinterim dividend of 6.00 US cents makes a total for 2010 of 15.82 US cents.
The final dividend is expected to be paid, subject to shareholder approval, on 19 May 2011 to shareholders on the RegisterofMembers atthe close ofbusiness on3 May2011.
Key Performance Indicators The Directors Report includes a number of measures that management use as key performance indicators including those financial performance indicators set out in the Financial Summary above.
A discussion of the reasons for, calculation and limitations of the key financial performance indicators is set out below.
The Group is focused on continued delivery of sustainable profitable growth through four strategic pillars Customer led, Efficient, Investing forgrowth and Aligned as explained on page 4 of this document.
From these four strategic pillars, a scorecard has been developed which identifies the specific functional strategic imperatives for each part of the Group.
The performance against the scorecard is evaluated against a series of financial and non-financial indicators and measures.
